Latest News for: mrna

Edit

FDA snubs mRNA flu vax, trial Lax. Big Pharma threatens American Jobs (VIDEO)

The Liberty Beacon 15 Feb 2026
FDA snubs mRNA flu vax, trial Lax ... – which Moderna posted a week later on its COVID resources page for some reason – says the FDA warned the company before it even started the mRNA flu trial that the proposed design raised red flags.
Edit

Earnings Transcript (MRNA USQ Transcript 2026 02 13) (Moderna Inc)

Public Technologies 14 Feb 2026
MRNA.OQ - Q4 2025 Moderna Inc Earnings Call ... Before I start a review of 2025, I want to express all this appointment to the FDA, who will be able to file later on our full program, mRNA-1010 ... mRNA-4106.
Edit

FDA rejects Moderna’s mRNA flu vaccine application - for reasons with no basis in the law

Mount Carmel Register 13 Feb 2026
The move signals an escalation in the agency’s efforts to interfere with established procedures for testing and approving vaccines ... .
Edit

Why did the U.S. FDA decline to review the new mRNA influenza vaccine?

The Hindu 13 Feb 2026
The debate here is not about the legitimacy of mRNA vaccines. It is about whether the right comparator was chosen in a clinical trial — and whether that design is sufficient for regulatory review ....
Edit

Moderna (MRNA) Stock Slips Despite Beating Q4 Revenue and Earnings Estimates

BitRSS 13 Feb 2026
TLDR Moderna reported Q4 revenue of $678 million, beating Wall Street estimates of $626.1 million, driven by COVID-19 vaccine sales The company posted a quarterly loss of $2.11 per share, narrower than the $2.54 per share loss analysts expected... .
Edit

Moderna (NASDAQ:MRNA) Exceeds Q4 CY2025 Expectations

The Call 13 Feb 2026
Moderna (MRNA) Q4 CY2025 Highlights. ... MRNA) develops messenger RNA (mRNA) medicines that direct the body's cells to produce proteins with therapeutic or preventive benefits for various diseases.Revenue Growth.
Edit

8000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities (Leverage Shares plc)

Public Technologies 13 Feb 2026
8000 Leverage Shares 3x Long Moderna (MRNA) ETP Securities ... Leverage Shares 3x Long Moderna (MRNA) ETP Securities ... To track the iSTOXX Leveraged 3x MRNA Index ... Leverage Shares 3x Long Moderna (MRNA) ETP Securities, ISIN.
Edit

FDA Declines to Review Moderna’s mRNA Flu Vaccine Application

US News 12 Feb 2026
By Carole Tanzer Miller HealthDay ReporterTHURSDAY, Feb. 12, 2025 (HealthDay News) — In a major blow to vaccine development, the U.S. Food and Drug... .
Edit

Doctor concerned FDA refusal to review mRNA flu vaccine will affect other research

Baltimore Sun 12 Feb 2026
Moderna and Pfizer-BioNTech already produce mRNA-based COVID vaccines, but there’s no licensed mRNA flu vaccine on the market ... Berkley said this “worrisome” refusal by the FDA could further slow vaccine research, including mRNA studies.
Edit

NanoViricides Files for Orphan Drug Status as U.S. Measles Cases Surge (MRNA,QNCX)

GetNews 12 Feb 2026
"Biotech Stock - NNVC". "NV-387, as an effective drug would be an important tool to fight Measles resurgence in the USA and worldwide, when approved," said Anil R ... (NYSE American ... Even more alarming ... Diwan, PhD ... Beyond Measles ... MRNA), BioNTech SE (NASDAQ.
Edit

Aspen flags interim earnings slide but sticks to growth outlook

Moneyweb 12 Feb 2026
Weaker six-month performance is partly due to once-off restructuring costs related to manufacturing facilities in SA and France ... .
Edit

What To Expect From Moderna’s (MRNA) Q4 Earnings

The Call 12 Feb 2026
Biotechnology company Moderna (NASDAQ. MRNA) will be reporting results this Friday before market hours. Here’s what to look for ... Is Moderna a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members ... More News ... .
×